June 19, 2013
A Pennsylvania federal judge Wednesday gave final approval to a $35 million settlement ending a class action alleging GlaxoSmithKline PLC used improper means to block its rivals from bringing generic versions of its allergy medication Flonase to market.
May 24, 2013
Flonase purchasers urged a Pennsylvania federal court Thursday to sanction objectors to a $35 million class action settlement of allegations that GlaxoSmithKline PLC improperly delayed market entry of a generic nasal spray, saying the two objectors and their attorneys ignored a court order.
January 15, 2013
A Pennsylvania federal judge on Monday approved a settlement between GlaxoSmithKline PLC and two groups of plaintiffs in an antitrust class action accusing the pharmaceutical giant of improperly blocking rivals from bringing generic versions of allergy medication Flonase to market.
November 01, 2012
A Pennsylvania federal judge struck a blow to GlaxoSmithKline PLC on Thursday, ruling that plaintiffs in a class action accusing it of illegally blocking development of a generic Flonase could tap former U.S. Food and Drug Administration chief David Kessler as an expert witness.
June 19, 2012
A Pennsylvania federal judge certified a limited class of indirect purchasers of Flonase in five states on Monday as part of a suit accusing GlaxoSmithKline PLC of improperly blocking rivals from bringing generic versions of the nasal spray to market.
September 26, 2011
A Pennsylvania federal judge on Monday issued a split ruling on GlaxoSmithKline PLC's bid for summary judgment in four health care funds' antitrust class action alleging it improperly delayed sales of a generic version of Flonase, striking some claims while keeping others alive.
June 02, 2011
GlaxoSmithKline PLC on Thursday lost a bid for summary judgment in three antitrust cases pending in Pennsylvania that allege the company delayed sales of a generic version of Flonase by filing baseless petitions with the U.S. Food and Drug Administration.